TAILORx Results at 2018 ASCO Annual Meeting

Share this article

Largest-Ever Breast Cancer Treatment Study Designed to Assess the Effect of Chemotherapy for Patients with Intermediate Oncotype DX Breast Recurrence Score Results

The much-anticipated results of the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, will be presented by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) during the Plenary Session at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting on June 3. The clinical trial was independently designed and conducted by ECOG-ACRIN and sponsored by the National Cancer Institute (NCI). The goal of this trial—the largest-ever breast cancer treatment study— is to gain more precise information on the effect of chemotherapy, if any, for early-stage breast cancer patients with Oncotype DX Breast Recurrence Score results of 11 to 25.

With advocates playing a major role in the design, implementation, and funding of the trial, TAILORx is expected to establish a new standard of care for breast cancer patients, identifying more precisely which patients can effectively use hormone therapy alone and avoid the negative effects of chemotherapy, and which patients will benefit from chemotherapy. These findings are expected to help doctors ensure the right treatment for the right patient.

Enrolling more than 10,000 patients in 6 countries, the primary study group were patients with Recurrence Score results from 11 to 25. Patient were randomized to receive hormonal therapy with or without chemotherapy and were followed for approximately 9 years on average. It is estimated that this group represents approximately 260,000 women diagnosed each year globally.

For additional updates, you can follow us on Twitter (@GenomicHealth) and Facebook with #TAILORx. If you’ll be at ASCO this year, be sure to check out the presentation!

For those of you unable to attend ASCO or interested in learning more about the study results, we will be hosting a webinar on Monday, June 11 at 10 am PST. Hope you can join us!

Oncotype DX My Colon Cancer Coach